Patient samples andprimary culture. BM or blood samples from 24 consenting AML patients were collected in heparinized tubes before any therapy. From these 24 patients, 16 were AML3 or APL. and 8 other AML subtypes (3 AMLI, 3 AML2, I AML4, I AML5). The diagnosis was established by morphologic, according to the FAB criteria,' and cytogenetic criteria. Hematologic characteristics of the APL patients are summarized in Table 1 .
Acute promyelocytic leukemia (APL) is a homogeneous subgroup of acute myeloid leukemias (AMLs) characterized by the presence of the t(15.17) translocation and the resulting promyelocytic myeloid leukemia/retinoic acid receptor a (PML/RARa) fusion proteins. To date APL is the only AML that is sufficiently sensitive t o all-trans retinoic acid's (ATRA) differentiating effect. In vivo ATRA alone achieves complete remission in most APL patients. However, failure or partial responses are observed and the molecular basis of the absence of ATRA response in these patients has not been determined. To gain insights in the cell growth and differentiation of APL cells, expression of hematopoietic growth factors (HGF) shown t o be produced by leukemic cells (interleukinlp [IL-lp] , IL-6, tumor necrosis factor a (TNFa), granulocyte colony-stimulating factor [G-CSF], granulocyte-macrophage CUTE MYELOID LEUKEMIA (AML) is a malignant process that results from the accumulation in the blood and bone marrow (BM) of myeloid precursor cells characterized by abnormal growth and differentiation arrest. Both autocrine and paracrine hypotheses have been brought forward to suggest possible mechanisms for the transformation and invasive process. AML cells have been shown to express the genes or produce a variety of hematopoietic growth factors (HGFs), including granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF),' and cytokines such as interleukin-l (IL-l), IL-6,2-5 and tumor necrosis factor cu (TNFcu) .' Possible use of these factors by the AML cells themselves (GM-CSF, G-CSF, IL-6, IL-I) or by accessory cells (TNFcu, IL-l) may be responsible for both the autocrine/paracrine growth stimulation of the AML cell^,'^*^^^^ and the induction of leukemic cell differentiation. ' Little data concerning the expression and secretion pattern of growth factors by acute promyelocytic leukemia (APL) cells have been reported in the literature. APL, the AML3 French-American-British (FAB) classification subtype,R is a rare subgroup of AML (less than 10%) characterized by colony-stimulating factor [GM-CSF], and IL-3) was studied in 16 APL samples. Twelve APL cases expressed IL-lp, IL-6, and TNFa, but not G-CSF, GM-CSF, and IL-3. These cases achieved complete remission with ATRA therapy. The four remaining patients (either TNFa negative or G-CSF, GM-CSF or IL-3 positive) did not achieve complete remission with ATRA. In all cases, in vivo response t o ATRA therapy was correlated to the in vitro differentiation effect of all-trans retinoic acid mol/L. Thus, ATRA differentiation induction was strongly correlated to the HGF expression ( P < .0001). These results suggest that the presence or absence of HGF's expression by APL cells may contribute to the therapeutic effect of ATRA in this disease. phenotypic and genetic markers. The presence of the t( 15; 17) translocation and the identification of promyelocytic myeloid leukemidretinoic acid receptor a (PMWRARcu) fusion transcripts in APL patients strongly support the hypothesis that both the t( 15;17), and thus PMLRARcu, play a crucial role in the leukemogenesis of this disease.' Clinically, APL is characterized by hemorrhagic episodes caused by disseminated intravascular coagulation (DIC) and primary fibrinolysis,"' with an accumulation of hypergranular promyelocytes in the BM. Furthermore, APL cells are specifically responsive to all-trans retinoic acid (ATRA) and this characteristic has allowed the first differentiation therapy with retinoic acid."," However, failure or partial responses are observed and, though this has most frequently been reported in patients at second or third relapse," the molecular basis of the absence of ATRA response in these patients has not been determined. The present investigation was initiated to characterize the expression and production of HGF by APL cells to gain further insights into the leukemogenesis and RA sensitivity of this leukemic subtype. clear cells. After incubation, cell aliquots were taken for cell viability, RNA extraction, and detection of CSF, and cytokine production was performed in the supernatants. For each sample, differentiation with ATRA was assessed at day 5 of culture by morphology, and the generation of superoxide anion 0 ' -production was visualized by the nitroblue tetrazolium reduction assay as already de~cribed.'~ Cell viability was assessed by the trypan blue exclusion dye test. Proliferation curves were established for each case and an index ratio (viable cell count after 72 hours versus cell count at hour 0) was calc~lated.'~ Culture of control hematopoietic cells and cell lines. Normal peripheral blood lymphomononuclear cells were isolated from heparinized normal blood samples after Ficoll-Hypaque gradient. Then, the purified cells were stimulated with phorbol 12-myristate 13acetate 10"' mol/L (PMA) and phytohemagglutinin 2 pg/mL (PHA) for 6 hours, in the same medium used for AML cell culture. The promyelocytic cell line NB4 (a gift from M. Lanotte, Paris, France) was grown in RPM1 1640 medium supplemented with 15% FCS and the 5637 human bladder carcinoma cell line was grown in RPM1 1640 with 5% FCS.
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Biologic assay for G-CSF. G-CSF levels in supernatants collected from the leukemic cell culture after 72 hours were estimated by monitoring the proliferation of NFS-60 cells. The leukemic cell culture supernatants were concentrated (10-to 40-fold) by ultrafiltration with a Centriprep concentrator 10 (Amicon, Danvers, MA) to increase the detectable level of G-CSF. NFS-60 cells (2 X lo4) together with 25 pL of concentrated supernatants were cultured in each well of a microtiter plate at 37°C for 48 hours in humidified 5% CO2. Then 10 pL of M l T (3[4,5-dimethyl-2-thiazolyl-2,5-diphenyl-2Hltetrazolium bromide) were added. The plate was incubated for 5 hours at 37°C. Dimethylsulfoxide (125 pL) was added and the optic density was measured at 550 nm. Thus, samples to be. tested were titrated and related to an internal standard preparation. The sensitivity of this G-CSF assay was shown to be 10 pg/mL. The interassay coefficient of variation at level of 100 pg/mL was less than 10 (n = 6). As positive controls, cell culture mediums from lymphomononuclear cells stimulated by PMA and PHA and 5637 cell line were collected and tested.
GM-CSF, IL-3, IL-IP, TNFa and IL-6 enzyme-linked immunosorbent assay (ELISA)
. GM-CSF levels in the leukemic cell culture supernatants were estimated by an ELISA kit from Endogen (Boston, MA), and IL-3 levels by an ELISA kit from Amersham (Buckinghamshire, UK). For IL-l@, TNFa, and IL-6 levels, we have used ELISA kits from British Biotechnology (Oxford, England). GM-CSF, IL-3, IL-ID, and IL-6 ELISA were sensitive down to a concentration of 3 pg/mL and for TNFa ELISA, sensitivity was shown to be 12 pg/mL. For a secretion level of 100 pg/mL, the interassay coefficient of variation was less than 10 (n = 6). As positive controls, culture mediums from lymphomononuclear cells stimulated by PMA and PHA and 5637 cell line were collected and tested. Concentrated leukemic cell culture supernatants were used for GM-CSF and IL-3 detection. The results were expressed in pg/mL and in pg/106 cells, but no difference between these expressions were observed.
Northern blot analysis. Total cellular RNA from AML blasts was prepared by the guanidium isothiocyanate/cesium chloride centrifugation method as described by Davis et Briefly, 20 or 30 pg of RNA were size fractionated by agarose gel electrophoresis after denaturation in formamide loading buffer and transferred onto nitrocellulose membranes. These filters were prehybridized and hybridized at 65°C overnight in buffers containing 6X sodium chloride/ sodium citrate (SSC), 0.2% sodium dodecyl sulfate (SDS), and lox Denhart's solution. DNA probes were ['*P]-labeled by the multirandom priming method. After hybridization, the filters were washed under stringent conditions in 2X SSC, 0.1% SDS for 10 minutes twice at room temperature and then in 0.1 X SSC, 0.1 % SDS at 65°C for 10 minutes. The filters were autoradiographed at -80°C with intensifying screens for 2 days. As positive control for screening test, RNA from PMA-and PHA-stimulated lymphomononuclear cells and from the 5637 cell line were used.
DNA probes. cDNA probes for G-CSF and GM-CSF were kindly provided by Glaxo Laboratories (Lausanne, Switzerland).
cDNA probes for IL-lP, TNFa, and IL-6 were obtained from British Biotechnology. A rat glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probe was used to rehybridize the filters and normalize RNA expression.
Reverse transcription polymerase chain reaction (RT-PCR).
For personal use only. on October 22, 2017. by guest www.bloodjournal.org pnol/L of random hexamers (Pharmacia). The cDNA fragments were amplified by using 2.5 U of Thermus aquaticus (Taq) polymerase (Perkin Elmer-Cetus, Norwalk. CT) and 30 pmol of each specific primer for one cytokine in a total volume of 50 pL containing 1 X PCR buffer (10 mmol/L TRIS HCI, 50 mmol/L KCI). Reaction times consisted of 30 cycles (1 minute at 94°C. 2 minutes at 60°C or 55°C. 3 minutes at 72°C) and at the end 7 minutes at 72°C. Ten microliters of the amplified products was electrophoresed on 2% agarose gel stained with ethidium bromide.
The gels were transferred onto a nylon filter and hybridized to 5' end-labeled oligonucleotides with 32P using polynucleotide kinase for 30 minutes. Then the filters were washed and exposed to Kodak X-OMAT film (Eastman-Kodak, Rochester, NY) at -80°C with intensifying screens for a specific number of hours. Contamination was avoided by strict technical methods. In all experiments, two negative controls were carried through all the steps with the other samples. Confirmation of the results was assessed by performing the RT-PCR at least twice for each primer pair.
Primers used for the PCR were as follows: G-CSF, 5' CCCCCT-GGGCCCTGCCAGC 3', 5' CTGCCAGATGGTGGTGGCA 3'; GTTGCACAGG 3'; IL-3, IL-ID, TNFcu, and IL-6 primers were purchased from Clontech Laboratories (Palo Alto, CA). Oligonucleotide probes were as follows: G-CSF, 5' GTGAGGAAGATCCA-GM-CSF. 5' AGAGACACTGCTGCTGAGA 3'. 5' ATAATCTGG-GGGCGA 3'; GM-CSF, 5' ACCTGCCTACAGACCCGCCT 3'; IL-3. 5' CAAGACATTCTGATGGAAAA 3'; IL-ID, 5' CCATAT-GAACTGAAAGCTCT 3'; TNFcY, 5' CTGCACTTTGGAGTG-ATCGG 3'; IL-6, GCCAGAGCTGTGCAGATGAGTAC 5'.
Immunoenzymaric staining of TNFcu. Cytocentrifuged APL cell preparations were fixed in acetone, air dried, and stocked at -20°C until use. lmmunostaining was performed by the alkaline phosphatase antialkaline phosphatase (APAAP) procedure as previously described.'" The TNFcr antibodies were purchased from Genzyme (Cambridge, MA).
RESULTS
In vivo and in vitro charncteristics of ~k e
APL CUSES sludied. (Table l) . Sixteen APL cases were studied (patients I through 16). All patients were cytologically defined as APL leukemia; one case presented with a t( 11;17) translocation." Nine cases showed increased white blood cell (WBC) counts at presentation. All patients were treated with all-trans retinoic acid according to the previously published protocols."." Only four cases (patients 2, 6, 8, 13) did not achieve complete remission with ATRA therapy alone. Leukemic cell suspension culture was performed in all cases at diagnosis. Four samples (patients 2, 6, 8, 13) showed poor to no differentiation (49%, 34%, 40%, 0% of nitroblue tetrazolium (NBT) positive cells respectively) in the presence of ATRA IO-(' mol/L, corroborating the absence of in vivo ATRA efficacy. Ten cases showed spontaneous increase of viable cells in vitro (index ratio 21.2) (Fig l ) . Four of these cases (patients 1, 7, 9, 16) had an index ratio greater than 1.4. However, increased WBC at diagnosis was not correlated to the spontaneous increase of cell number in the suspension culture.
Secretion of HGF (IL-I@, TNFa, IL-6, G-CSF, GM-CSF, and IL-3) by APL cells.
Secretion of HGF was studied in culture supernatants of highly enriched blast cell populations of seven APL patients (patients 1 through 4 and 14 through 16). All of these seven cases secreted IL-I@ (median level, 1 1 pg/mL), TNFa (median level, 25 pg/mL). and IL-6 (me- 
Fig 2. Secretion levels of IL-lp, TNFa, IL-6, and CSFs (G-CSF, GM-CSF, IL-3) by APL cells and non-APL cells. APL*, ATRA-responsive APL (patients 1, 3, 4, and 14 to 16). Secretion analysis was made after 72 hours of cell culture, by ELlSA kits for IL-lp, TNFa, IL-6, IL-3, and GM-CSF, and by biologic assay for G-CSF. Values represent means of triplicate wells.
dian level, 66 pg/mL) (Fig 2) . Out of these seven cases, one case secreted IL-3 and GM-CSF (patient 2), and no cases secreted G-CSF. Case 2 did not respond to ATRA in vitro and in vivo. When kinetic studies (day 0 to day 6) were performed, secretion of IL-lp, IL-6, and TNFa was shown to be stable and not induced by the culture. Immunoenzymatic staining with TNFa antibodies in APL cells confirmed that APL cells are in fact responsible for the TNFa secretion detected (Fig 3) . Study of the NB4 promyelocytic cell line supernatant detected IL-lp, TNFa, and IL-6, but no G-CSF, GM-CSF, and IL-3 (data not shown).
Expression of HGF (IL-ID, TNFa, IL-6, G-CSF, GM-CSF, and IL-3) by APL cells.
To further characterise the presence or absence of HGF by APL cells, mRNA expression studies were performed. L -l p , TNFa, and IL-6 RNA levels were detectable by RT-PCR ( Fig 4B) and Northern blotting analysis (Fig 4A) , the latter confirming the normal size of the transcripts. Expression of IL-lp, TNFa, and IL-6 gene was analyzed in 13 APL cases (patients 1 through 13). IL-lP and IL-6 were detected in all APL cases, and TNFa in 11. Gene expression analysis of these HGFs in cells freshly isolated showed that APL cells spontaneously expressed IL-lp, TNFa, and IL-6 (data not shown). Compared with the positive controls (the 5637 cell line and lymphomononuclear cells stimulated by PMA and PHA), no 3267 G-CSF and GM-CSF mRNA expression could be detected by Northern blotting analysis in APL cells ( Fig 4A) .
To increase RNA sensitivity detection, RT-PCR was performed ( Fig 4B) . G-CSF mRNA was detected in only one case of the 13 samples studied (patient 6), GM-CSF mRNA in another case (patient 2) and IL-3 mRNA in 3 cases (patients 2, 6, and 13).
In summary, of the 16 APL cases tested for expression andor secretion of HGF, 12 cases (80%) coexpressed or cosecreted IL-lp, TNFa, and IL-6, but not G-CSF, GM-CSF, and IL-3. Furthermore, when expression and secretion could be performed in the same sample, presence or absence of gene expression was always associated with the release or absence of the corresponding protein.
Expression and secretion of HGF by non-APL cells. In eight non-APL samples tested, CSF expression was detected in four cases (one case, G-CSF; one case, GM-CSF; one case, G-CSF + GM-CSF; and one case, G-CSF + GM-CSF + IL-3) (data not shown). All cases expressed IL-1p and IL-6 genes, but only four cases the TNFa gene (Fig 4) . Higher levels of CSFs and cytokines were observed in these non-APL cases as compared with APL cases (Fig 2) . Only one case (AML2) expressed IL-lp, TNFa, IL-6, but no CSFs. Leukemic cell infiltration and leukemic cell purification were the same in this non-APL population as for the APL samples, implying that random contamination by normal HGF-secreting cells cannot explain the difference between APL and non-APL samples.
HGFproduction by AML cells and in vitro characteristics. (Fig 1) In vitro cell growth and viability of AML cells was studied in a suspension culture system with standard condition medium by comparing viable cell counts at different time intervals with the number of seeded cells at day 0 of culture. Compared with non-APL cases, APL cells showed a better survivaUgrowth in suspension culture. Only 3 APL cases had an index ratio less than 1 (patients 2, 8, 13 ). Among the 10 cases that showed in vitro leukemic cell growth (patients 1, 3 through 7, 9, 10, 12, 16), 9 cases expressed IL-lp, TNFa, and IL-6, but not CSFs.
ATRA sensitivity was also analyzed. Induction of differentiation was assessed by morphologic and functional criteria (NBT test). Twelve of the 16 APL cases studied (patients 1,3 through 5, 7, 9 through 12, 14 through 16) achieved differentiation in vitro in the presence of ATRA mom (mean of 94 2 6% NBT positive cells) and complete remission with ATRA therapy in vivo. These cases all coexpressed or coproduced Lip, TNFa, and L-6, but not CSFs. The 4 APL cases that failed to respond significantly to ATRA therapy never exceeded more than 50% of differentiation and either expressed CSFs or did not produce TNFa. Non-APL cases did not show significant induction of differentiation by ATRA (varied from 0% to 20% with a mean of 5.5%) in vitro. Thus, ATRA differentiation induction was strongly correlated to the pattern of HGF expression (P = . OOO1 Fisher test).
DISCUSSION
This is the first study describing the coexpression of HGF in the APL subgroup of AML. We observed that of the 16 APL cases surveyed in this study, all but 4 cases were (IL- l p , IL-6, TNFa) positive and (G-CSF, GM-CSF, IL-3) negative. These results are corroborated by the presence of TNFa in the APL cells by immunostaining, and by preliminary studies from our laboratory and other published data hinting at the absence of detectable G-CSF and GM-CSF levels and increased L -6 levelsr7 in the serum of APL patients. This pattern was specifically correlated to ATRA sensitivity in vitro and in vivo. Interestingly, the four patients whose leukemic cells did not express TNFa or did express CSFs, did not achieve complete remission with ATRA therapy. Likewise non-APL cases that do not respond to ATRA, did not show the HGF expression pattern. Thus, part of the effect of ATRA's efficacy may be the result of the growth factor pattern spontaneously expressed by APL cells. Differentiation of leukemic cells (cell lines and fresh blast in primary culture) can be induced by CSFs, TNFa, and interferons in association with all-trans retinoic acid (ATRA).'8-20 The presence of these HGF expressions by APL cells may be involved in the in vitro sensitivity of APL cells to differentiate in the presence of ATRA. To evaluate the potential role of any of these growth factors, we have initiated in vitro assays using antibodies and antisense oligonucleotide probes to suppress each growth factor individually. In fact, the two patients whose cells did not express TNFa did not respond in vivo to ATRA therapy. A further question asked by the results presented here is whether the expression of HGF by APL cells has a relevance to these cells' proliferation or survival features in vitro. APL cells are noted to have a low doubling time:' and absence of autonomous growth.22 These characteristics may be related to previously reported high levels of transforming growth facto? and to TNFa production and absence of IL-3, GM-CSF, and G-CSF secretion shown in this study. Nevertheless, in the presence of added CSFs such as GM-CSF, APL cells are able to produce colonyforming unit-leukemia coloniesz4 and to show increased cell growth. '4 This growth induction in the presence of GM-CSF is not surprising because we have shown APL cells to express high atkity GM-CSF receptors.z In addition, the secretion of IL-lp and IL-6 by APL cells may, alone or in cooperation with the CSFs present in the culture medium, explain the good survival of APL cells in suspension culture. 26 Clinically, APL is characterized by the presence of blood coagulation disorders and hyperleukocytosis at onset, mainly in the AML3 variant subtype." IL-10 has been reported to be linked to DIC in AML patient^.'^ The constant presence of IL-lp in APL cells may explain the predisposition of APL patients to present altered blood coagulation parameters. Contrary to what may have been expected, the cytokine/ CSF production did not correlate with high WBC count at presentation. This suggests that other factors determinant for leukemic cell proliferation, such as egress from the BM, adhesion, and migration are probably involved. One of ATRA therapy's main side effects is the induced ATRA syndrome (pulmonary infiltrates, respiratory distress)28 and the increase of peripheral blast cells. The fact that APL cells express HGFs ( L -l p , TNFa, and E-6) that are involved in leukocyte activationz9"' may propose that an abnormal modulation of these factors by retinoic acid may provoke these side effects. The data presented here offer a model to study the mechanisms of induction of these side effects and identify potential preventive or curative therapies. Thus, the secretion or absence of secretion of HGF by APL cells may be determinant for the survival, multiplication, and differentiation capacity of these cells. We suggest that the resulting expression of growth factors by APL cells may contribute to the clinical and biologic features of the disease and that the cause of this expression may be related to the molecular characteristics of APL. Answering these questions will be of utmost clinical and scientilic relevance. For personal use only. on October 22, 2017. by guest www.bloodjournal.org From
